Citations

Clear

3030 citation(s) found for "Susan, M".

Abstract OT2-19-05: A phase I/II trial of abemaciclib and T-DM1 in women and men with HER2-positive advanced or metastatic breast cancer that has progressed on treatment with a taxane, trastuzumab and pertuzumab (THP) (ACCRU-BR-1801)
Sullivan, Ciara C O, He, Jun , Leon‐Ferre, Roberto A. , Chalasani, Pratima, Yaşar, Demet Gökalp, Anderson, D. Mark , Stella, Philip J., Jaslowski, Anthony J., Tannenbaum, Susan , Saverimuthu, Angela, Northfelt, Donald W. , Moreno‐Aspitia, Alvaro , Liu, Minetta C. , Wang, Liewei , Suman, Vera J. , Kalari, Krishna R. , Villasboas, José C. , Anderson, Daniel M, Carter, Jodi M. , Lou, Zhenkun , Goetz, Matthew P.

Mayo Clinic

Cancer Research | March 8, 2022 | Volume: 82 | Issue: 4_Supplement | Pages: OT2-19-05-OT2-19-05

10.1158/1538-7445.sabcs21-ot2-19-05 Get It

Abstract Background: Although major advances have been made in the treatment of HER2+ metastatic breast cancer (MBC), the goal of care remains largely palliative, therefore better treatments are needed. Given encouraging preclinical and clinical data, the combination of cyclin dependent 4/6 kinase inhibitors and HER2-directed therapy is further being evaluated in this trial. Trial Design: In this phase I/II multicenter trial, we will determine the maximum tolerated dose (MTD) of abemaciclib (Abem) combined with T-DM1. Three Abem dose levels will be examined, 50 mg, 100 mg and 150 mg. The phase 2 portion of this trial will examine whether PFS is increased with addition of Abem to T-DM1 in two pt cohorts - those with ER+ HER2+ MBC and those with ER-HER2+ MBC. For phase 2, a pre-registration biopsy is required to confirm ER and HER2-status and to determine levels of tumor infiltrating lymphocytes; vimentin (an epithelial-mesenchymal transition marker); and CD8 and FOXP3 expression. Blood samples will be collected pretreatment , at 6 weeks, and at progression for all pts. Eligibility Criteria: Phase I&II: All pts must have HER2+ MBC per ASCO-CAP guidelines and prior treatment with a taxane, trastuzumab and pertuzumab. For the phase Iportion, pts can have measurable or non-measurable disease with no restriction on the number of prior lines of therapy. In the phase II portion, pts must have measurable disease with ≤1-2 prior lines of chemotherapy alone, ≤1 HER2-directed therapy alone, and/or chemotherapy with HER2-directed therapies. There is no limit on prior endocrine therapy. Specific Aims: The primary objective of the phase II trial is to assess whether addition of Abem to T-DM1 increases PFS in one or both patient cohorts. Secondary objectives include an assessment of toxicity, objective response rates and overall survival. Correlative studies will assess the association between baseline TIL levels, vimentin expression, and CD8/FOXP3 expression with PFS. Changes in peripheral blood mononuclear cells, CTCs, ctDNA and serum thymidine kinase 1 during the course of treatment will be examined to determine if there is a link with PFS outcomes overall and separately for each cohort. Pharmacogenomic studies will determine if pts with the FCGR3A-158 polymorphism derive less benefit from T-DM1 and have inferior PFS outcomes compared with pts who do not have this polymorphism. Statistical Methods:Phase I: Standard 3+3 design, with dose limiting toxicities as per protocol. Phase II: For each pt cohort, a stratified randomization scheme will be used to assign pts to treatment with liver mets as a stratification factor. For each pt cohort, a stratified log rank test will be used to assess whether PFS is increased with the addition of Abem to T-DM1. A non-binding futility analysis will be applied in each cohort after 58 events in the ER+ HER2+ MBC study cohort and 48 events in the ER- HER2+ MBC study cohort. Present Accrual: 0; target accrual: minimal 120 pts., maximal 140 pts CohortOne-sidedalphaPowerAccrual Period (accrual rate)Follow-up after close of enrollmentPFS with T-DM1PFS with abema and T-DM1Number of eligible patientsER+/HER2+0.100.912 months (5-6 pts per month)12 months12 weeks24 weeks64 (32 per arm)ER-/HER2+0.100.8512 months (3-4 pts per month)12 months6 weeks12 weeks50 (25 pts per arm) Citation Format: Ciara C O Sullivan, Jun He, Vera J Suman, Krishna R Kalari, Roberto A Leon-Ferre, Jose C Villasboas-Bisneto, Pratima Chalasani, Demet Gokalp Yasar, Daniel M Anderson, Philip J Stella, Anthony J Jaslowski, Susan H Tannenbaum, Angela Saverimuthu, Donald Northfelt, Alvaro Moreno-Aspitia, Jodi M Carter, Minetta C Liu, Liewei Wang, Zhenkun Lou, Matthew P Goetz. A phase I/II trial of abemaciclib and T-DM1 in women and men with HER2-positive advanced or metastatic breast cancer that has progressed on treatment with a taxane, trastuzumab and pertuzumab (THP) (ACCRU-BR-1801) [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr OT2-19-05.
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease
Gorelik, Mark , Chung, Sharon A. , Ardalan, Kaveh , Friedman, Kevin G. , Hayward, Kristen , Imundo, Lisa F., Lapidus, Sivia , Kim, Susan , Son, Mary Beth F. , Sule, Sangeeta , Mater, Heather Van, Yildirim‐Toruner, Cagri , Langford, Carol A. , Maz, Mehrdad , Abril, Andy , Archer, Amy M., Conn, Doyt L. , Full, Kathy A., Grayson, Peter C. , Ibarra, Maria, Rhee, Rennie L. , Stone, John H. , Vitobaldi, Omar I., Warner, Ann, Byram, Kevin , Husainat, Nedaa , James, Karen , Kalot, Mohamad A. , Lin, Yih Chang, Springer, Jason , Turgunbaev, Marat, Villa‐Forte, Alexandra, Turner, Amy S. , Lapidus, Sivia K , Kim, Susan , Son, Mary Beth , Sule, Sangeeta , Maz, Mehrdad , Conn, Doyt L , Grayson, Peter C , Rhee, Rennie L , Stone, John H , Dua, Anisha B , Husainat, Nedaa M , Turner, Amy S , Mustafa, Reem A , Springer, Jason M , Kalot, Mohamad A , Binstadt, Bryce A. , Tremoulet, Adriana H. , Guyatt, Gordon , Merkel, Peter A. , Seo, Philip , Sundel, Robert P. , Warner, Ann, Dua, Anisha B.

Mayo Clinic

Arthritis Care & Research | March 8, 2022 | Volume: 74 | Issue: 4 | Pages: 538-548

10.1002/acr.24838 | PMID 35257507 Get It

Objective To provide evidence‐based recommendations and expert guidance for the management of Kawasaki disease (KD), focusing on clinical scenarios more commonly addressed by rheumatologists. Methods Sixteen clinical questions regarding diagnostic testing, treatment, and management of KD were developed in the Patient/Population, Intervention, Comparison, and Outcomes (PICO) question format. Systematic literature reviews were conducted for each PICO question. We used the Grading of Recommendations, Assessment, Development and Evaluation method to assess the quality of evidence and formulate recommendations. Each recommendation required consensus from at least 70% of the Voting Panel. Results We present 1 good practice statement, 11 recommendations, and 1 ungraded position statement to guide the management of KD and clinical scenarios of suspected KD. These recommendations for KD are focused on situations in which input from rheumatologists may be requested by other managing specialists, such as in cases of treatment‐refractory, severe, or complicated KD. The good practice statement affirms that all patients with KD should receive initial treatment with intravenous immunoglobulin (IVIG). In addition, we developed 7 strong and 4 conditional recommendations for the management of KD or suspected KD. Strong recommendations include prompt treatment of incomplete KD, treatment with aspirin, and obtaining an echocardiogram in the setting of unexplained macrophage activation syndrome or shock. Conditional recommendations include use of IVIG with other adjuvant agents for patients with KD and high‐risk features of IVIG resistance and/or coronary artery aneurysms. These recommendations endorse minimizing risk to the patient by using established therapy promptly at disease onset and identifying situations in which adjunctive therapy may be warranted. Conclusion These recommendations provide guidance regarding diagnostic strategies, use of pharmacologic agents, and use of echocardiography in patients with suspected or confirmed KD.
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease
Gorelik, Mark , Chung, Sharon A. , Ardalan, Kaveh , Friedman, Kevin G. , Hayward, Kristen , Imundo, Lisa F., Lapidus, Sivia , Kim, Susan , Son, Mary Beth F. , Sule, Sangeeta , Mater, Heather Van, Yildirim‐Toruner, Cagri , Langford, Carol A. , Maz, Mehrdad , Abril, Andy , Archer, Amy M., Conn, Doyt L. , Full, Kathy A., Grayson, Peter C. , Ibarra, Maria, Rhee, Rennie L. , Stone, John H. , Vitobaldi, Omar I., Warner, Ann, Byram, Kevin , Dua, Anisha B. , Husainat, Nedaa , Kalot, Mohamad A. , Lin, Yih Chang, Springer, Jason , Turgunbaev, Marat, Villa‐Forte, Alexandra, Turner, Amy S. , Lapidus, Sivia K , Kim, Susan , Son, Mary Beth , Sule, Sangeeta , Maz, Mehrdad , Conn, Doyt L , Grayson, Peter C , Rhee, Rennie L , Stone, John H , Dua, Anisha B , Husainat, Nedaa M , Turner, Amy S , Mustafa, Reem A , Springer, Jason M , Kalot, Mohamad A , Binstadt, Bryce A. , Tremoulet, Adriana H. , Guyatt, Gordon , Merkel, Peter A. , Seo, Philip , Sundel, Robert P. , Warner, Ann, James, Karen E.

Mayo Clinic

Arthritis & Rheumatology | March 8, 2022 | Volume: 74 | Issue: 4 | Pages: 586-596

10.1002/art.42041 | PMID 35257501 Get It

Objective To provide evidence‐based recommendations and expert guidance for the management of Kawasaki disease (KD), focusing on clinical scenarios more commonly addressed by rheumatologists. Methods Sixteen clinical questions regarding diagnostic testing, treatment, and management of KD were developed in the Patient/Population, Intervention, Comparison, and Outcomes (PICO) question format. Systematic literature reviews were conducted for each PICO question. We used the Grading of Recommendations, Assessment, Development and Evaluation method to assess the quality of evidence and formulate recommendations. Each recommendation required consensus from at least 70% of the Voting Panel. Results We present 1 good practice statement, 11 recommendations, and 1 ungraded position statement to guide the management of KD and clinical scenarios of suspected KD. These recommendations for KD are focused on situations in which input from rheumatologists may be requested by other managing specialists, such as in cases of treatment‐refractory, severe, or complicated KD. The good practice statement affirms that all patients with KD should receive initial treatment with intravenous immunoglobulin (IVIG). In addition, we developed 7 strong and 4 conditional recommendations for the management of KD or suspected KD. Strong recommendations include prompt treatment of incomplete KD, treatment with aspirin, and obtaining an echocardiogram in the setting of unexplained macrophage activation syndrome or shock. Conditional recommendations include use of IVIG with other adjuvant agents for patients with KD and high‐risk features of IVIG resistance and/or coronary artery aneurysms. These recommendations endorse minimizing risk to the patient by using established therapy promptly at disease onset and identifying situations in which adjunctive therapy may be warranted. Conclusion These recommendations provide guidance regarding diagnostic strategies, use of pharmacologic agents, and use of echocardiography in patients with suspected or confirmed KD.
National Network of Depression Centers' Recommendations on Harmonizing Clinical Documentation of Electroconvulsive Therapy
Zandi, Peter P. , Morreale, Michael , Reti, Irving M. , Maixner, Daniel F. , McDonald, William M. , Patel, Paresh D. , Achtyes, Eric D. , Bhati, Mahendra T. , Carr, Brent R. , Conroy, Susan K. , Cristancho, Mario A. , Dubin, Marc J. , Francis, Andrew , Glazer, Kara, Ingram, Wendy Marie , Khurshid, Khurshid, McClintock, Shawn M. , Reeves, Kevin , Rodriguez, Nelson F., Sampson, Shirlene , Seiner, Stephen J., Smetana, Roy W., Soda, Takahiro , Trapp, Nicholas T. , Wright, Jesse H. , Husain, Mustafa M. , Weiner, Richard D. , Pinjari, Omar F. , Selek, Salih , Sheline, Yvette I. , Smetana, Roy W.

Mayo Clinic

The Journal of ECT | March 4, 2022 | Volume: 38 | Issue: 3 | Pages: 159-164

10.1097/yct.0000000000000840 | PMID 35704844 Get It

Abstract Electroconvulsive therapy (ECT) is a highly therapeutic and cost-effective treatment for severe and/or treatment-resistant major depression. However, because of the varied clinical practices, there is a great deal of heterogeneity in how ECT is delivered and documented. This represents both an opportunity to study how differences in implementation influence clinical outcomes and a challenge for carrying out coordinated quality improvement and research efforts across multiple ECT centers. The National Network of Depression Centers, a consortium of 26+ US academic medical centers of excellence providing care for patients with mood disorders, formed a task group with the goals of promoting best clinical practices for the delivery of ECT and to facilitate large-scale, multisite quality improvement and research to advance more effective and safe use of this treatment modality. The National Network of Depression Centers Task Group on ECT set out to define best practices for harmonizing the clinical documentation of ECT across treatment centers to promote clinical interoperability and facilitate a nationwide collaboration that would enable multisite quality improvement and longitudinal research in real-world settings. This article reports on the work of this effort. It focuses on the use of ECT for major depressive disorder, which accounts for the majority of ECT referrals in most countries. However, most of the recommendations on clinical documentation proposed herein will be applicable to the use of ECT for any of its indications.
Integration of mental health and supportive care in individuals with schizophrenia and cancer: Assertive community treatment model
Taylor-Desir, Monica , Sawchuk, Craig N. , Crane, Sarah J. , Carroll, Jamie L., Evans, Whitney S., Bogucki, Olivia E. , Taylor-Desir, Monica J., Carroll, Jamie M. , Lewis, Susan E. , Lapid, Maria I.

Mayo Clinic

Psycho-Oncology | February 25, 2022 | Volume: 32 | Issue: 7 | Pages: 1142-1144

10.1002/pon.5911 | PMID 35212429 Get It

Key points Persons with severe and persistent mental illness (SPMI) experience disparities in accessing and initiating cancer treatment The assertive community treatment (ACT) model promotes the integration of physical and mental health care and improves the quality of life for a patient diagnosed with cancer The ACT model is essential in promoting decisional capacity of those with SPMI and cancer diagnoses The ability to access 24‐h support from the ACT model provides psychological support to patients dealing with chronic physical health diagnoses Collaboration between cancer treatment teams and the multidisciplinary ACT team can improve treatment engagement and enhance a patient's natural support system
Embolic Stroke in Setting of Iliac Vein Stenosis in an Avid Cyclist
Chhabra, Nikita , Blech, Benzion , Fortuin, David, Wilansky, Susan , Dumitrașcu, Oana , Demaerschalk, Bart M.

Mayo Clinic

The Neurohospitalist | February 20, 2022 | Volume: 12 | Issue: 2 | Pages: 413-416

10.1177/19418744211067910 | PMID 35419129 Get It

External iliac vein stenosis related to cycling has rarely been reported as a cause of deep vein thrombosis. Ischemic stroke occurring in this condition due to paradoxical embolism across a preexisting patent foramen ovale (PFO) has yet to be reported. Here we report a case of embolic ischemic strokes in a young, avid cyclist with no prior known vascular risk factors. A thorough cerebrovascular workup revealed a right-to-left shunt on transesophageal echocardiogram that prompted venous thrombosis evaluation. Pelvic MR venogram demonstrated a 3.5 cm high-grade stenosis of the right external iliac vein, concerning for possible prior thrombotic disease. His strokes were deemed most likely a result of paradoxical emboli originating in the pelvis at the site of right external iliac vein stenosis. The patient ultimately opted for PFO closure for secondary stroke prevention, as he wished to continue daily cycling. This case highlights the importance of neurohospitalists considering iliac vein stenosis as a potential cause of embolic stroke of undetermined source, especially in young patients who are avid cyclists, as part of a thorough vascular workup.
AAPM task group report 302: Surface‐guided radiotherapy
Al‐Hallaq, Hania , Gutiérrez, Alonso N. , Havnen‐Smith, Amanda, Higgins, Susan A., Kügele, M. , Padilla, Laura , Pawlicki, Todd , Remmes, Nicholas B. , Smith, Koren, Tomé, Wolfgang A. , Havnen-Smith, Amanda, Remmes, Nicholas, Cerviño, Laura , Tang, Xiaoli

Mayo Clinic

Medical Physics | February 18, 2022 | Volume: 49 | Issue: 4 | Pages: No page available

10.1002/mp.15532 | PMID 35179229 Get It

Abstract The clinical use of surface imaging has increased dramatically, with demonstrated utility for initial patient positioning, real‐time motion monitoring, and beam gating in a variety of anatomical sites. The Therapy Physics Subcommittee and the Imaging for Treatment Verification Working Group of the American Association of Physicists in Medicine commissioned Task Group 302 to review the current clinical uses of surface imaging and emerging clinical applications. The specific charge of this task group was to provide technical guidelines for clinical indications of use for general positioning, breast deep‐inspiration breath hold treatment, and frameless stereotactic radiosurgery. Additionally, the task group was charged with providing commissioning and on‐going quality assurance (QA) requirements for surface‐guided radiation therapy (SGRT) as part of a comprehensive QA program including risk assessment. Workflow considerations for other anatomic sites and for computed tomography simulation, including motion management, are also discussed. Finally, developing clinical applications, such as stereotactic body radiotherapy (SBRT) or proton radiotherapy, are presented. The recommendations made in this report, which are summarized at the end of the report, are applicable to all video‐based SGRT systems available at the time of writing.
Review: Self-management training in type 2 diabetes mellitus is effective in the short term
Bjornsen, Susan S., Montori, Víctor M.

Mayo Clinic

ACP Journal Club | February 17, 2022 | Volume: 135 | Issue: 2 | Pages: 45

10.7326/acpjc-2001-135-2-045 Get It

Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants
Lowry, Kathryn P. , Geuzinge, H. Amarens , Stout, Natasha K. , Alagöz, Oğuzhan , Hampton, John M. , Koning, Harry J. de , Miglioretti, Diana L. , Ravesteyn, Nicolien T. van , Sprague, Brian L. , Tosteson, Anna N.A. , Weaver, Donald L. , Yaffe, Martin J. , Mandelblatt, Jeanne S. , Kurian, Allison W. , Auer, Paul L. , Berstein, Leslie, Carter, Brian D., Gaudet, Mia M. , Haiman, Christopher, Jacobs, Eric J. , John, Esther M. , Lindström, Sara , Martínez, Elena, Patel, Alpa V. , Reid, Sonya , Taylor, Jack A. , Teras, Lauren R., Vachon, Celine M. , Yao, Song, Ziogas, Argyrios, Goldgar, David E. , Chen, Chen , Chen, C , Miglioretti, Diana L , John, Esther M , Taylor, Jack A , de Koning, Harry J , Kurian, Allison W , Kerlikowske, Karla , Schechter, Clyde B. , Trentham‐Dietz, Amy , Yeh, Jennifer M. , Couch, Fergus J. , Hu, Chunling , Kraft, Peter , Polley, Eric C. , Robson, Mark E. , Hart, Steven N. , Nathanson, Katherine L. , Domchek, Susan M. , Ambrosone, Christine B. , Anton‐Culver, Hoda , Bandera, Elisa V. , Bertrand, Kimberly A. , Burnside, Elizabeth S. , Eliassen, A. Heather , Hodge, James M. , Hunter, David J. , Kooperberg, Charles , Lacey, James V. , Marchand, Loı̈c Le , Ma, Huiyan , Neuhausen, Susan L. , Newcomb, Polly A. , O’Brien, Katie M. , Olson, Janet E. , Ong, Irene M. , Pal, Tuya , Palmer, Julie R. , Rosenberg, Lynn A. , Sandler, Dale P. , Tamimi, Rulla M. , Teras, Lauren R. , Vachon, Celine M. , Weinberg, Clarice R. , Yadav, Siddhartha , Yao, Song , Weitzel, Jeffrey N.

Mayo Clinic

JAMA Oncology | February 17, 2022 | Volume: 8 | Issue: 4 | Pages: 587

10.1001/jamaoncol.2021.6204 | PMID 35175286 Get It

Clinical Activity of Single Dose Systemic Oncolytic VSV Virotherapy in Patients with Relapsed Refractory T-Cell Lymphoma
Peng, Kah Whye, Witzig, Thomas E. , Broski, Stephen M. , Villasboas, José C. , Patnaik, Mrinal M. , Leung, Nelson , Ansell, Stephen M. , Zhang, Lianwen , Brunton, Bethany, Giers, Marissa, Ginos, Brenda, Dueck, Amylou C. , Geyer, Susan M. , Warsame, Rahma , Hayman, Suzanne R. , Dingli, David , Kumar, Shaji , Bergsagel, P. Leif , Kourelis, Taxiarchis , Kapoor, Prashant , Kyle, Robert A. , Lin, Yi , Siddiqui, Mustaqeem , Fonder, Amie , Hobbs, Miriam, Hwa, Yi L. , Naik, Shruthi , Russell, Stephen J. , Lacy, Martha Q. , Bergsagel, P. Leif , Witzig, T.E. , Broski, Stephen M , Villasboas, Jose Caetano , Paludo, Jonas , Patnaik, Mrinal , Dispenzieri, Angela , Leung, Nelson , Buadi, Francis K , Bennani, N Nora , Balakrishnan, Baskar , Dueck, A. C. , Gertz, Morie A , Warsame, Rahma , Kumar, Shaji K , Munoz, Javier L, Kourelis, Taxiarchis , Muchtar, E , Siddiqui, Mustaqeem A , Fonder, Amie , Russell, Stephen J , Lacy, Martha Q , Dingli, David , Lin, Yi , Cook, Joselle , Paludo, Jonas , Rajkumar, S. Vincent , Dispenzieri, Angela , Buadi, Francis K. , Bennani, N. Nora , Packiriswamy, Nandakumar , Balakrishnan, Baskar , Gertz, Morie A. , Go, Ronald S. , Muñoz, Javier , Gonsalves, Wilson I. , Muchtar, Eli

Mayo Clinic

Blood Advances | February 17, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2021006631 | PMID 35175355 Get It

Clinical success with intravenous (IV) oncolytic virotherapy (OV) has to date been anecdotal. Here, we conducted a phase 1 clinical trial of systemic OV therapy and investigated the mechanisms of action in responding T-cell lymphoma (TCL) patients. A single IV dose of VSV-IFNβ-NIS was administered to patients with relapsed refractory hematologic malignancies to determine safety and efficacy across 4 dose levels (DL). Correlative studies were undertaken to evaluate viremia, virus shedding, virus replication and immune responses. Fifteen patients received VSV-IFNβ-NIS (7 multiple myeloma, 7 TCL, 1 acute myeloid leukemia); 3 patients were treated at each DL1 through DL3 (0.05, 0.17, and 0.5 x 1011 TCID50), and 6 at DL4 (1.7 x 1011 TCID50). There were no dose limiting toxicities. 3 of 7 patients with TCL had RECIST responses: a 3-month PR at DL2, a 6-month PR and a durable CR ongoing at 20 months at DL4. Viremia peaked at the end of infusion and no infectious virus shedding was detected. Plasma interferon-β levels, a biomarker of VSV-IFNβ-NIS replication, peaked between 4h and 48h post infusion. The patient with CR had robust viral replication with increased ell free DNA in her plasma, a very high peak IFNβ level of 18,213 pg/ml, a strong anti-VSV neutralizing antibody response, and increased numbers of tumor reactive T-cells. VSV-IFNβ-NIS as a single agent was effective in patients with TCL resulting in durable disease remissions in heavily pretreated patients. Correlative analyses suggest that responses may be due to a combination of direct oncolytic tumor destruction and immune-mediated tumor control. Further clinical testing is warranted. (This trial is registered at www.clinicaltrials.gov as NCT03017820).